Rohit Gosain/LinkedIn
Oct 27, 2025, 08:00
Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation
Rohit Gosain, Medical Director of Roswell Park Comprehensive Cancer Center, posted on LinkedIn:
“Revumenib is now FDA approved for R/R AML with NPM1 mutation (approved for KMT2A translocation previously).
– ORR 46.9%
– Response seen in all subgroups (comutations, previous HSCT, or high number of prior lines of Rx).”
Stay informed with Hemostasis Today.
-
Nov 6, 2025, 08:24Jacqui McCallum Reflects on Meeting with The Royal Melbourne Hospital Stroke and Neurology Ward Team
-
Nov 6, 2025, 08:17Maxime Dely: The True Heroes of Blood Donation Are Them!
-
Nov 6, 2025, 07:11Francesco Giurazza on Radial Access for Liver Transarterial Chemoembolization
-
Nov 6, 2025, 07:04Andrea Van Beek: Proud to be a Certified Anticoagulation Care Provider (CACP)!
-
Nov 6, 2025, 06:57Jian-Ke Tie’s Team on Comorbidity of VitK-dependent Clotting Factors Deficiency and Chondrodysplasia Punctata
-
Nov 6, 2025, 04:17Aakanksha A To Present Insights from ASH Education Social Media Initiative at 67th ASH Meeting
-
Nov 6, 2025, 04:03Yaping Zhang on Two-Way GPIb-IX Signaling in Platelet Activation and VWF Binding
-
Nov 6, 2025, 03:38Thierry Burnouf on Platelet-Derived Extracellular Vesicles and Their Role in Neurogenesis
-
Nov 6, 2025, 03:29Shubham Misra to Present 3 Abstracts at International Stroke Conference 2026
Nov 6, 2025, 08:17
Nov 5, 2025, 10:45
Nov 5, 2025, 10:43